» Authors » Mary Beth Humphrey

Mary Beth Humphrey

Explore the profile of Mary Beth Humphrey including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 62
Citations 3087
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Griffin T, Komaravolu R, Lopes E, Mehta-Dsouza P, Conner T, Kovats T, et al.
Sci Rep . 2025 Jan; 15(1):2428. PMID: 39827311
We hypothesized that daily exercise promotes joint health by upregulating anti-inflammatory mediators via adaptive molecular and metabolic changes in the infrapatellar fat pad (IFP). We tested this hypothesis by conducting...
2.
Javed L, Khakwani A, Khan U, Humphrey M
Am J Med Sci . 2024 Aug; 369(1):1-13. PMID: 39214248
Medication-induced osteoporosis leads to substantial fracture morbidity. With polypharmacy and the aging population in the United States, significant increases in medication-associated fractures are predicted. The most common medication to cause...
3.
Ramakrishnan G, Berry W, Pacherille A, Kerr W, Chisholm J, Pedicone C, et al.
Mol Immunol . 2024 Apr; 170:35-45. PMID: 38613944
Microglia play a pivotal role in the pathology of Alzheimer's Disease (AD), with the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) central to their neuroprotective functions. The R47H variant...
4.
Humphrey M, Russell L, Danila M, Fink H, Guyatt G, Cannon M, et al.
Arthritis Care Res (Hoboken) . 2023 Oct; 75(12):2405-2419. PMID: 37884467
Objective: The objective is to update recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP) for patients with rheumatic or nonrheumatic conditions receiving >3 months treatment with glucocorticoids (GCs) ≥2.5...
5.
Humphrey M, Russell L, Danila M, Fink H, Guyatt G, Cannon M, et al.
Arthritis Rheumatol . 2023 Oct; 75(12):2088-2102. PMID: 37845798
Objective: The objective is to update recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP) for patients with rheumatic or nonrheumatic conditions receiving >3 months treatment with glucocorticoids (GCs) ≥2.5...
6.
Akram B, Khan M, Humphrey M
J Clin Rheumatol . 2023 Sep; 30(2):e42-e45. PMID: 37723618
Human immunodeficiency virus (HIV) is widely prevalent among the world population. Although, historically, it has been linked to opportunistic infections in keeping with immunodeficiency and immune dysregulation, it has also...
7.
Houser J, Patel M, Wright K, Onopiuk M, Tsiokas L, Humphrey M
Blood Cells Mol Dis . 2023 Jun; 102:102760. PMID: 37267696
Hematopoiesis and lineage commitment are regulated by several conserved cell-intrinsic signaling pathways, including MAPKs and β-catenin/TCF/LEF. The Inhibitor of MyoD Family A (I-MFA), a transcriptional repressor and tumor suppressor gene,...
8.
Gentry C, Thind S, Williams 2nd R, Hendrickson S, Kurdgelashvili G, Humphrey M
Am J Med Sci . 2022 Sep; 365(1):19-25. PMID: 36103912
Background: The primary purpose of the current study was to examine whether patients with rheumatologic conditions receiving only chronic hydroxychloroquine therapy for their disease are at less risk of developing...
9.
Elkholey K, Niewiadomska M, Morris L, Whyte S, Houser J, Humphrey M, et al.
Circ Heart Fail . 2022 Jul; 15(8):e009288. PMID: 35862007
Background: A systemic proinflammatory state plays a central role in the development of heart failure with preserved ejection fraction (HFpEF). Low-level transcutaneous vagus nerve stimulation (LLTS) suppresses inflammation in animals...
10.
Stavrakis S, Elkholey K, Morris L, Niewiadomska M, Asad Z, Humphrey M
J Am Heart Assoc . 2022 Jan; 11(3):e023582. PMID: 35023349
Background A systemic proinflammatory state plays a central role in the development of heart failure with preserved ejection fraction. Low-level transcutaneous vagus nerve stimulation suppresses inflammation in humans. We conducted...